Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer

British Journal of Cancer

Volumn 97, Issue 7, 2007, Pages 851-856

  Takayama, T ^a   Sato, Y ^a   Sagawa, T ^a   Okamoto, T ^a   Nagashima, H ^a   Takahashi, Y ^b   Ohnuma, H ^b   Kuroiwa, G ^c   Miyanishi, K ^a   Takimoto, R ^a   Matsunaga, T ^a   Kato, J ^a   Yamaguchi, K ^a   Hirata, K ^a   Niitsu, Y ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO CANCER CENTER   (Japan)

^c Higashi Sapporo Hospital   (Japan)

Author keywords

Cisplatin; Docetaxel; Downstaging; Gastric cancer; S 1; VEGF

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; DOCETAXEL; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GASTRECTOMY; HUMAN; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; STOMACH CANCER; TUMOR GROWTH;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG COMBINATIONS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INTESTINAL NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; OXONIC ACID; STOMACH NEOPLASMS; TAXOIDS; TEGAFUR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34948836748     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603957     Document Type: Article

References (34)

1. Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M, Urrea P (2005a) Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 23: 6957-6965
2. Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E (2005b) Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 23: 5660-5667
3. Ajani JA, Lee FC, Singh DA, Haller DG, Lenz HJ, Benson III AB, Yanagihara R, Phan AT, Yao JC, Strumberg D (2006) Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24: 663-667
4. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ (2004) Multivariate prognostic factor analysis in locally advanced and meta-static esophago-gastric cancer - pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22: 2395-2403
5. Dickson JL, Cunningham D (2004) Systemic treatment of gastric cancer. Eur J Gastroenterol Hepatol 16: 255-263
6. Einzig AI, Neuberg D, Remick SC, Karp DD, O'Dwyer PJ, Stewart JA, Benson III AB (1996) Phase II trial of docetaxel (taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the eastern cooperative oncology group (ECOG) results of protocol E1293. Med Oncol 13: 87-93
7. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, Heuman R (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8: 163-168
8. Gong W, Wang L, Yao JC, Ajani JA, Wei D, Aldape KD, Xie K, Sawaya R, Huang S (2005) Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res 11: 1386-1393
9. Hironaka S, Boku N, Ohtsu A, Koizumi W, Tanabe S, Shirao K (2002) Significance of vascular endothelial growth factor (VEGF) in gastric cancer (GC) patients (pts) treated with S-1, a new oral fluoropyrimidine, with/without cisplatin (CDDP). Proc Soc Clin Oncol 21: 606
10. Hotchkiss KA, Ashton AW, Mahmood R, Russell RG, Sparano JA, Schwartz EL (2002) Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (taxotere): association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther 1: 1191- 1200
11. Hyodo I, Nishina T, Moriwaki T, Endo S, Terao T, Hirao K, Nasu J, Hirasaki S, Endo H, Masumoto T, Tajiri H, Kurita A (2003) A phase I study of S-1 combined with weekly cisplatin for metastatic gastric cancer in an outpatient setting. Eur J Cancer 39: 2328-2333
12. Inokuchi M, Yamashita T, Yamada H, Kojima K, Ichikawa W, Nihei Z, Kawano T, Sugihara K (2006) Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. Br J Cancer 94: 1130-1135
13. Kim JG, Ryoo BY, Park YH, Kim BS, Kim TY, Im YH, Kang YK (2007) Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol. Online publication
14. Koizumi W, Kurihara M, Nakano S, Hasegawa K (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 cooperative gastric cancer study group. Oncology 58: 191-197
15. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, Shirao K, Matsumura Y, Gotoh M (2003) Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 89: 2207-2212
16. Konturek PC, Konturek SJ, Brzozowski T (2006) Gastric cancer and Helicobacter pylori infection. J Physiol Pharmacol 57(Suppl 3): 51-65
17. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72: 37-41
18. Murakami M, Ota K, Miyazaki T, Niitsu Y, Wakui A, Yokoyama M, Kanamaru R, Futatsuki K, Akazawa S, Sakai Y (1987) Sequential methotrexate-5-fluorouracil (MTX-5-FU) treatment of patients with advanced gastric and colorectal cancer. Sequential methotrexate-5-FU study group. Gan To Kagaku Ryoho 14: 2482-2490
19. Nagashima F, Ohtsu A, Yoshida S, Ito K (2005) Japanese nationwide postmarketing survey of S-1 in patients with advanced gastric cancer. Gastric Cancer 8: 6-11
20. Nishi M, Omori Y, Miwa Y (1999) Response Assessment of Chemotherapy and Radiotherapy for Gastric Carcinoma Part IV, pp 89-100. Tokyo: Kanehara Shuppan
21. Ohtsu A, Yoshida S, Saijo N (2006) Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol 24: 2188-2196
22. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71: 587-591
23. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Herrmann R, Honegger H, Cavalli F, Alberto P, Castiglione M, Goldhirsch A (2000) Docetaxel (taxotere) - cisplatin (TC): an effective drug combination in gastric carcinoma Swiss group for Clinical Cancer Research (SAKK), and the European Institute Of Oncology (EIO). Ann Oncol 11: 301-306
24. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 Mtegafur-0.4 Mgimestat-1 Motastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720
25. Shah MA, Schwartz GK (2004) Treatment of metastatic esophagus and gastric cancer. Semin Oncol 31: 574-587
26. Shirao K, Shimada Y, Kondo H, Saito D, Yamao T, Ono H, Yokoyama T, Fukuda H, Oka M, Watanabe Y, Ohtsu A, Boku N, Fujii T, Oda Y, Muro K, Yoshida S (1997) Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 15: 921-927
27. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557
28. Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, Wanders J, Franklin H, LeBail N, Verweij J (1994) Docetaxel (taxotere) in advanced gastric cancer: results of a phase II clinical trial EORTC early clinical trials group. Br J Cancer 70: 380-383
29. Thuss-Patience PC, Kretzschmar A, Repp M, Kingreen D, Hennesser D, Micheel S, Pink D, Scholz C, Dorken B, Reichardt P (2005) Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol 23: 494-501
30. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA, V325 Study group (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 24: 4991- 4997
31. World Health Organization (1979) WHO handbook for reporting results of cancer treatment. WHO Offset Publication No.48. Geneva, Switzerland: World Health Organization
32. Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, Miyata Y, Taguchi T (2001) Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 12: 1133- 1137
33. Yamaguchi K, Shimamura T, Hyodo I, Koizumi W, Doi T, Narahara H, Komatsu Y, Kato T, Saitoh S, Akiya T, Munakata M, Miyata Y, Maeda Y, Takiuchi H, Nakano S, Esaki T, Kinjo F, Sakata Y (2006) Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 94: 1803-1808
34. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J, Nishiyama M (2006) Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12: 3402- 3407